

ePoster number	Presenting author	Poster title	Presentation order	ePoster screen	Theme	Moderator
2.001eP	Craig McDonald	Rationale, Study Design and Baseline Characteristics in the GRAND CANYON Clinical Trial of Sev	1	Screen 1	Becker muscular dystrophy	Matteo Garibaldi
2.002eP	Hiroyuki Shibasaki	Patient and public involvement in Becker muscular dystrophy: establishment and outcomes of	2	Screen 1	Becker muscular dystrophy	Matteo Garibaldi
2.003eP	Andres Eduardo Nascimento Osorio	Thromboembolic burden and stroke risk in pediatric LMNA-related congenital muscular dystro	3	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.004eP	Didem Ardiçlı	Expanding clinical and genetic spectrum of alpha-dystroglycanopathies: single-center experien	4	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.005eP	Kumiko Ishiguro	Study of motor and respiratory function in Ullrich congenital muscular dystrophy in Japan	5	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.006eP	Serkan Kirik	A Novel Homozygous INPP5K Mutation in Siblings with Congenital Cataract and Muscular Dyst	6	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.007eP	Andreea Seferian	Baseline data from pediatric patients with LAMA2 related dystrophies enrolled in a prospective	7	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.008eP	Dilek Cavusoglu	Compound heterozygous POMT1 mutations in a boy with muscular dystrophy-dystroglycanopa	8	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.009eP	Tetiana Shkliarska	Clinical presentation of a patient with TRIP4-associated congenital muscular dystrophy	9	Screen 1	CMD - Clinical care and case reports	Matteo Garibaldi
2.010eP	Gulcin Akinci	Barriers to delivery of standard-of-care physiotherapy for Duchenne muscular dystrophy: a nat	1	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.012eP	Marika Pane	Development of an Italian registry to assess natural history in Duchenne muscular dystrophy: a	2	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.013eP	Cameron Wade	Tolerability of Givinstat in Combination with Exon-Skipping Therapy in Individuals with Duche	3	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.014eP	Rageen Rajendram	Machine learning prediction of non-invasive ventilation initiation in Duchenne muscular dystro	4	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.015eP	Christian De Goede	Hydrotherapy in Duchenne muscular dystrophy, a systematic review	5	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.017eP	Cameron Wade	Fatal Fat Embolism Syndrome without Recognized Fracture in Patients with Duchenne Muscula	6	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.019eP	Vineeth Jaison	Impact of functional mobility on dental aesthetic index (DAI) scores in children with Duchenne	7	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.020eP	Kotaro Arioka	Long-Term Follow-up of Communication Methods Utilizing Residual Functions in Patients with	8	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.021eP	Gokcen Oz Tuncer	School attendance in Duchenne muscular dystrophy	9	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.022eP	Gokcen Oz Tuncer	Genetic and clinical spectra of dystrophinopathies in Turkish children	10	Screen 2	DMD - clinical care and case reports	Edoardo Malfatti
2.023eP	Aysima Özçelik	Evaluation of the psychosocial status and quality of life of healthy siblings of children diagnose	1	Screen 3	DMD - clinical care and case reports	Yukiko Hayashi
2.024eP	Bilge Özgör	Pan-immune-inflammation value predicts earlier loss of ambulation in Duchenne muscular dys	2	Screen 3	DMD - clinical care and case reports	Yukiko Hayashi
2.025eP	Meirong Liu	Clinical, pathological, and genetic characteristics of x-linked dilated cardiomyopathy caused by	3	Screen 3	DMD - clinical care and case reports	Yukiko Hayashi
2.026eP	Monique Driesssen van Haeringen	Establishing the diagnosis of dystrophinopathy in a female manifesting carrier: a multimodal di	4	Screen 3	DMD - clinical care and case reports	Yukiko Hayashi
2.027eP	Erika Finanger	Post delandistrogene moxeparvovec-rokl immune mediated myositis in Duchenne muscular dy	5	Screen 3	DMD - clinical care and case reports	Yukiko Hayashi
2.028eP	Zurisdai Gonzalez Castillo	Advanced cardiac therapies in the dystrophinopathy spectrum: a review of two-cases	6	Screen 3	DMD - clinical care and case reports	Yukiko Hayashi
2.029eP	Numan Bulut	Defining plantar pressure distribution in children with Duchenne muscular dystrophy and its as	7	Screen 3	DMD - imaging and outcome measures	Yukiko Hayashi
2.030eP	Meghan Moore Burk	Development and validation of a novel dystrophinopathy foot index (DFI) for comparison and s	8	Screen 3	DMD - imaging and outcome measures	Yukiko Hayashi
2.031eP	Satoshi Kuru	Evaluation of the efficacy of Viltolarsen to Duchenne muscular dystrophy using muscular imagi	9	Screen 3	DMD - imaging and outcome measures	Yukiko Hayashi
2.033eP	Kirandeep Sahajpal	Pre-implementation safety validation of governance-controlled AI for communication of emerg	1	Screen 4	DMD - treatments	Johann Böhm
2.034eP	Kaitlin Batley	Two-year motor function outcomes following treatment with delandistrogene moxeparvovec-r	2	Screen 4	DMD - treatments	Johann Böhm
2.035eP	Mihaela Cioclu	Therapeutic novelties in Duchenne muscular dystrophy – experience from a European expert c	3	Screen 4	DMD - treatments	Johann Böhm
2.036eP	Paul Horn	Assessing side effects of thrombocytopenia and hypertriglyceridemia for individuals with Duch	4	Screen 4	DMD - treatments	Johann Böhm
2.037eP	Akari Kawano	Safety of viltolarsen in patients with Duchenne muscular dystrophy in real-world clinical practic	5	Screen 4	DMD - treatments	Johann Böhm
2.038eP	Harumasa Nakamura	Real-world evidence of viltolarsen in Japanese boys with Duchenne muscular dystrophy: four-y	6	Screen 4	DMD - treatments	Johann Böhm
2.039eP	Eri Takeshita	Real world four-year outcomes on the efficacy and safety of viltolarsen for Duchenne muscular	7	Screen 4	DMD - treatments	Johann Böhm
2.040eP	Eugenio Mercuri	QTc distribution in Duchenne muscular dystrophy patients: implications for therapies with pote	8	Screen 4	DMD - treatments	Johann Böhm
2.041eP	John Brandsema	Trajectory of Performance of Upper Limb in patients with Duchenne muscular dystrophy treat	9	Screen 4	DMD - treatments	Johann Böhm
2.042eP	Nicolas Deconinck	Hematological effects of vamorolone in boys with Duchenne muscular dystrophy (DMD) – com	10	Screen 4	DMD - treatments	Johann Böhm
2.043eP	Kevin Larimore	Comprehensive panel of pharmacokinetic, pharmacodynamic, and biomarker measures drives	11	Screen 4	DMD - treatments	Johann Böhm
2.044eP	Crystal Proud	Pooled safety analysis from Phase 1 to Phase 3 clinical trials of delandistrogene moxeparvovec	12	Screen 4	DMD - treatments	Johann Böhm

2.045eP	Iva Holder	FORZETTO, a phase 3 study of z-rostudirsen in ambulatory males with DMD mutations amenab	1	Screen 5	DMD - treatments	Hermien Kan
2.047eP	Matthew Harmelink	Pharmacokinetics and pharmacodynamic effects of the POLARIS-101 (TM) rationally designed,	2	Screen 5	DMD - treatments	Hermien Kan
2.048eP	Nozomi Hayashiji	Development of a therapeutic approach for Duchenne muscular dystrophy based on the glycos	3	Screen 5	DMD - treatments	Hermien Kan
2.049eP	Ramla Omar	Enhancing antisense oligonucleotide efficacy in Duchenne muscular dystrophy by histone deac	4	Screen 5	DMD - treatments	Hermien Kan
2.050eP	Rachael Potter	Efficacy and safety of early intervention with delandistrogene moxeparvovec in DMDMDX mice	5	Screen 5	DMD - treatments	Hermien Kan
2.051eP	Satomi Shirakaki	Xanthine oxidoreductase inhibition improves cellular energetics and mitochondrial function in	6	Screen 5	DMD - treatments	Hermien Kan
2.052eP	Mario Amendola	CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy	7	Screen 5	DMD - treatments	Hermien Kan
2.053eP	Tatsuya Suzuki	Real-world characteristics and care patterns of DMD patients in Japan and the United States: a	8	Screen 5	DMD - treatments	Hermien Kan
2.054eP	Natalia Balamut	Safety and efficacy of viltolarsen in DMD therapy. Data from 4 years of real clinical practice in R	9	Screen 5	DMD - treatments	Hermien Kan
2.055eP	Tiberiu Loredan Stan	Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments	10	Screen 5	DMD - treatments	Hermien Kan
2.056eP	Matthew Harmelink	Positive preliminary liver safety profile using next-generation capsid POLARIS-101 in the SGT-00	11	Screen 5	DMD - treatments	Hermien Kan
2.065eP	Mario Amendola	CRISPR activation of utrophin as a mutation-independent approach for Duchenne muscular dys	12	Screen 5	DMD - treatments	Hermien Kan
2.057eP	Emma Heslop	Duchenne hub UK network enabling effective and efficient clinical trial set up and delivery	1	Screen 6	DMD - treatments	Corinna Preusse
2.058eP	Michinori Funato	Safety and efficacy of viltolarsen treatment in patients with Duchenne muscular dystrophy: a re	2	Screen 6	DMD - treatments	Corinna Preusse
2.059eP	Kevin Larimore	Muscle composition and muscle injury biomarkers improve with BMN 351 treatment	3	Screen 6	DMD - treatments	Corinna Preusse
2.060eP	Emma Niba	Generation of iPSC lines with a pathogenic DMD pseudoxon mutation c.9225-285A>G	4	Screen 6	DMD - treatments	Corinna Preusse
2.061eP	Robert Crozier	Real-world patient and treatment characteristics in children under 4 years old with Duchenne r	5	Screen 6	DMD - treatments	Corinna Preusse
2.062eP	Denise Quigley	Real-world patient and treatment characteristics in a non-ambulatory cohort ≥12 years old with	6	Screen 6	DMD - treatments	Corinna Preusse
2.063eP	Reema Flynn-Rizk	Building muscle, bridging models: an integrated platform for Duchenne muscular dystrophy ge	7	Screen 6	DMD - treatments	Corinna Preusse
2.064eP	Cuixia Tian	QTc prolongation in an Individual with Duchenne Muscular Dystrophy Treated with Givinstat	8	Screen 6	DMD - treatments	Corinna Preusse
2.067eP	Francesco Muntoni	Efficacy and safety of golodirsen and casimersen compared with placebo in Duchenne muscula	9	Screen 6	DMD - treatments	Corinna Preusse
2.068eP	Ryan Mitchell	Preclinical to human translation of regenerative index: quantification of progressive muscle deg	10	Screen 6	Dystrophinopathies	Corinna Preusse
2.069eP	Deirdre Merry	Dystrophin-deficient skeletal muscle is further stiffened by contraction-induced injury but is res	11	Screen 6	Dystrophinopathies	Corinna Preusse
2.070eP	Ainoa Tejedera-Villafranca	Real-time kinetic monitoring of sarcolemmal fragility in patient-derived DMD muscle-on-a-chip	12	Screen 6	Dystrophinopathies	Corinna Preusse
2.071eP	Francisco Agustin Cerra	Epilepsy in dystrophinopathies: prevalence, electroclinical features, and brain dystrophin isofo	1	Screen 7	Dystrophinopathies	Anne Schänzer
2.072eP	Tomonori Kitaura	Early cardiac dysfunction in mdx/Utrn-/- mice as a severe preclinical model for Duchenne mus	2	Screen 7	Dystrophinopathies	Anne Schänzer
2.073eP	Anne Bigot	Leveraging patient-derived myoblasts and FAPs to study neuromuscular diseases	3	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.074eP	Lyn Eigenfeldt	Acute H2O2 exposure remodels chromatin accessibility in skeletal muscle stem cells toward dif	4	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.075eP	Sohee Moon	p21 contributes to senescent myoblast persistence and impaired regeneration in age-related sa	5	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.076eP	Dwifrista Vani Pali	CCL5, a candidate gene associated with age-related sarcopenia, attenuates palmitic acid-induce	6	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.077eP	Masahiko Sato	N-acetylglucosamine induces coordinated flow-like migration of myoblasts underlying efficient	7	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.078eP	Ryohei Sakurao	Systematic evaluation of myotube formation and pepsin concentration dependency of plant-de	8	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.079eP	Pervin Dincer	Asymmetric nucleocytoplasmic transport of desmin: lack of karyopherin-independent import, a	9	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.080eP	Mayuu Iwai	Increased transient receptor potential melastatin 2 expression in a mouse model of inflamatc	10	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.081eP	Masaru Takatoya	Glutamine enhances myotube formation in C2C12 myoblasts through glutamine metabolism-m	11	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.082eP	Dipti Baskar	ANTXRopathies: a unified spectrum of ANTRX1 and ANTRX2 disorders driven by extracellular m	12	Screen 7	Pathophysiology of NMDs	Anne Schänzer
2.083eP	Nelsa Estrella	Machine learning-directed exercise protocol development for 3D neuromuscular junction tissu	1	Screen 8	Pathophysiology of NMDs	Akinori Uruha
2.084eP	Juzhen Chen	The preventive effects of mild hyperbaric oxygen environment on age-related sarcopenia throu	2	Screen 8	Pathophysiology of NMDs	Akinori Uruha
2.085eP	Courtney Shellenbarger	GLP-1 receptor agonist therapy in obesity with Duchenne muscular dystrophy: a case highlight	3	Screen 8	DMD - clinical care and case reports	Akinori Uruha
2.086eP	Sneha Sneha	Eco-friendly, home-based rehabilitation using calibrated DIY equipment for LGMD (R1-R5) and	4	Screen 8	Environmental Sustainability	Akinori Uruha
2.087eP	Jaakko Sarparanta	Printed versus electronic posters: Environmental footprint and other considerations	5	Screen 8	Environmental Sustainability	Akinori Uruha
2.088eP	Sami Tayb-Boulahfa	PHARMA solidaires, a circular social model for medical devices and parapharmaceutical redistr	6	Screen 8	Environmental Sustainability	Akinori Uruha
2.089eP	Jung Hwan Lee	The lipid paradox in sarcopenia: a nationwide mediation analysis of the role of body volume los	7	Screen 8	Environmental Sustainability	Akinori Uruha
2.090eP	Maggie Walter	Multidisciplinary Approach to Weight Management and Nutrition in genetic neuromuscular dis	8	Screen 8	Environmental Sustainability	Akinori Uruha